Presentation is loading. Please wait.

Presentation is loading. Please wait.

New Antimicrobials Agents Michael J. Tan, MD, FACP, FIDSA Associate Professor of Internal Medicine, Northeast Ohio Medical University Summa Health System,

Similar presentations


Presentation on theme: "New Antimicrobials Agents Michael J. Tan, MD, FACP, FIDSA Associate Professor of Internal Medicine, Northeast Ohio Medical University Summa Health System,"— Presentation transcript:

1 New Antimicrobials Agents Michael J. Tan, MD, FACP, FIDSA Associate Professor of Internal Medicine, Northeast Ohio Medical University Summa Health System, Akron, OH

2 Disclosures  Speaker Bureaus  Cubist  Pfizer  Actavis  The Medicines Company  Theravance  Research  Cubist  Merck

3 Which of the following is an approved indication for ceftolozane-tazobactam? A.Acute bacterial skin and skin structure infection B.Complicated intraabdominal infections C.Bacteremia due to methicillin-resistant Staphylococcus aureus D.Hospital acquired pneumonia due to resistant pseudomonas E.All of the above

4 Objectives  Review antimicrobials  New antimicrobials

5 Select New Antibacterial Agents Approved Since 1998 AntibacterialYearNovel Rifapentine1998No Quinupristin/dalfopristin1999No Moxifloxacin1999No Gatifloxacin*1999No Linezolid2000Yes Cefditoran pivoxil2001No Ertapenem2001No Gemifloxacin2003No Daptomycin2003Yes Telithromycin*2004No Tigecycline2005No Doripenem2007No Telavancin2009No Ceftaroline2010No Fidaxomicin2011Yes Tedizolid2014No Dalbavancin2014No Oritavancin2014No Ceftolozane/Tazobactam2014No Ceftazidime/Avibactam2015No Spellberg CID 2004, modified

6 Pneumococcal conjugate vaccine (PCV13)  CAPiTA trial  Looking at difference with vaccine containing serotype pneumococcal pneumonia 1 st episode confirmed vaccine type-CAP, 49 vs 90 (PCV13 vs. placebo) 1 st episode confirmed NB/NI/VT-CAP, 33 vs. 60 1 st episode of VT-IPD, 7 vs 28.  ACIP/CDC  Over 65: Give PCV13, follow with PPSV 23 (8wk)  Immunecompromised: Give PCV 13, follow with PPSV23.  Previous PPSV23: Give PCV13 (at least 1y if known), follow with PPSV 23 (at least 5 yr after previous PPSV23 and 8 wks after PCV13)  May have decreased efficacy with inactivated influenza vaccination  Officially: PPSV23 should follow PCV 13 by 12 mos (based on reimbursement, immunecompromised, min 8 weeks) 6

7 Pipeline  Gram positive agents:  Dalbavancin, oritavancin, tedizolid (all three approved 2014)  CDI agents  monoclonal antibody, non-toxigenic C diff, oxazolidinone with FQ moiety, Lipoglycopeptide  HCV  Multiple agents (new approvals 2014, 2015)  Gram negative agents:  Ceftolozane/tazobactam (CXA 201) (Approved December 2014)  Ceftazidime/avibactam (NXL104) (Approved February 2015)  Ceftaroline-avibactam  Imipenem/MK-7655  Plazomicin (Aminoglycoside)  Ervacycline (Fluorocycline)  Brilacidin (Peptide defense protein mimetic) Novel

8 Telavancin (Vibativ™)  Approved September 2009  Lipoglycopeptide, built on vancomycin  Cell wall and cell membrane active  Indications:  Complicated skin and skin structure infection due to certain Gram positives including MRSA  NEW 6/13: HABP/VABP caused by susceptible isolates of S aureus (including MRSA) when alternative treatments are not suitable  Dosing  10mg/kg IV q24h  Renal dosing necessary  Dialysis dosing not yet established

9 AEs  Teratogenic (but preg cat c!) in some animals  Nephrotoxicity  QTc prolongation (looks less than FQ)  Interference with INR, PT, PTT, without bleeding risk  Nausea/vomitting, taste disturbance, foamy urine  No increase in Red Man  Patients with pre-existing moderate-severe renal impairment (Crt Cl <=50), treated for HABP/VABP had higher mortality compared with vancomycin.

10 Telavancin  Unique aspects  Based on vancomycin, but varied mechanism Cell Wall and Cell membrane active  Another option for MRSA activity, some VRE  IV only  No need to check levels  Looks to be more effective than vanc in skin, but results not statistically significant.  Had issues with marketing and supply line  Now has 2 year supply available

11 Ceftaroline (Teflaro), Forest Pharmaceuticals  Cephalosporin ? Generation  Approved 10/29/2010  Indications:  Acute bacterial skin and skin structure infections (ABSSSI) MRSA, MSSA, Strep, E coli, K pneumo, K oxy.  Community-acquired bacterial pneumonia (CABP) MSSA, Pneumococcus (+/- bacteremia), H infl, K pneumo, K oxy, E coli  Dosing  600mg IV q12h over 1hr Crt Cl >50  400mg IV q12h over 1hr Crt Cl >30-<=50  300mg IV q12h over 1hr Crt Cl >=15, <=30  200mg IV q12h over 1hr ESRD, including HD. Teflaro PI

12 Ceftaroline Teflaro PI

13 Ceftaroline  Binds PBP2a, PBP2x  AEs  Well tolerated, no specific AE >5%  Nausea, diarrhea, rash, most common  No significant difference between ceftaroline and comparators, Vanc/Aztreonam, Ceftriaxone.  Pregnancy B  Minimal interactions with P450 drugs  Excretion: Primarily kidneys, 64% in urine unchanged. Teflaro PI

14 Ceftaroline-Unique Aspects  IV Only  No hepatic adjustment  Dose have renal dosing recommendations  Indicated for ABSSSI, CABP  In vitro activity vs. MRSA  Marginal at best for Enterococcus fecaelis, Minimal if any for E faecium.

15 Ceftolozane/Tazobactam (Zerbaxa)  Cubist, approved December 2014  Cephalosporin + B-lactamase inhibitor  Extended gram negative, P aeruginosa, ESBL activity  Indications (due to susceptible bacteria):  Complicated intraabdominal infection (CIAI) + metronidazole E cloacae, E coli, K pneumo, K oxytoca, P mirabilis, P aeruginosa, B fragilis, S anginosus, S constellatus, S salivarius  Complicated urinary tract infection E coli, K pneumo, P mirabilis, P aeruginosa  Dosages  Crt cl > 501.5g (1g/0.5) IV q8h  Crt cl 30-50750mg (500mg/250mg) IV q8h  Crt cl 15-29375mg (250mg/125mg) IV q8h  Crt cl <15750mg (500mg/250mg) IV x1, 150mg (100/50) q8h

16

17 Ceftolozane/Tazobactam (Zerbaxa)  Unique aspects  IV Only  Similar AE profile to other cephalosporins  Pregnancy Cat B  *Anaerobic activity, but studies done with metro  Increased ESBL activity  No KPC or metallo beta-lactamase activity  Retains activity against most resistant Pseudmonas  Geriatrics, renal impairment  In cIAI vs. meropenem, cure rate lower in 65 and older Not seen in cUTI  In cIAI vs. meropenem, cure rate lower in crt cl 30-50 Similar trend seen in cUTI vs. levoflox in crt cl 30-50

18 Ceftazidime/avibactam (Avycaz)  Actavis (now Allergan), approved February 2015  Cephalosporin (3 rd gen) with new B-lactamase inhibitor  Avibactam Inhibits AmpC, KPC, but NOT ESBL or NDM-1  Indications (due to susceptible bacteria), 18 and older  Complicated intra-abdominal infection, in combination with metronidazole (E coli, K pneumo, P mirabilis, Providencia stuartii, E cloacae, K oxytoca, P aeruginosa)  Complicated urinary tract infection, including pyelonephritis (E coli, K pneumo, Citrobacter koseri, Citrobacter, freundii, Proteus spp, E cloacae, E aerogenes, P aeruginosa  Dosages  2.5g (2g/0.5g) over 2h q8h

19 Ceftazidime/avibactam (Avycaz)  Dosages  >50mL/min2.5g (2g/0.5g) over 2h q8h  31-501.25g (1g/0.25g) over 2h q8h  16-300.94g (0.75g/0.19g) over 2h q12h  6-150.94g (0.75g/0.19g) over 2h q24h  Contraindications  Hypersensitivity to ceftaz/avi, ceftaz, cephs  Warnings  cIAI, cure rates lower in CrtCl 30-50 vs. >50. Dose in this subgroup was 33% less than what is recommended

20 ceftazidime avibactam

21 Ceftazidime/avibactam (Avycaz)  Unique aspects  IV Only  Similar AE profile to other cephalosporins  Pregnancy Cat B  Minimal anaerobic activity, need metro  Increased KPC/CRE activity  No ESBL or metallo beta-lactamase activity  Anti-Pseudmonal  EXPENSIVE

22 Tedizolid (Sivextro)  Approval for Acute bacterial skin and skin structure infection caused by susceptible bacteria  Gram positive and resistant GPC, including MRSA  2 nd of the oxazolidinone class  Once daily option  200 mg IV/PO q24h x6 days  HAP/VAP in development  Cat C 22

23 Tedizolid (Sivextro)  Unique aspects and potential concerns  Based on mouse studies, patients with neutropenia may have inadequate response to therapy  AE profile similar to linezolid  MIGHT: Have less hematologic side effects (duration dependent effect seen, but studies only for 6 days) Have similar peripheral and optic neuropathy issues Have less interaction with pressors Have less interaction with SSRI/MAO (SSRI/MAO patients excluded from study) Not be as good as linezolid for strep (by raw numbers)  Cost currently on par with linezolid, but oral linezolid went generic early 2015. 23

24 Dalbavancin (Dalvance)  Indication for acute bacterial skin and skin structure infections caused susceptible strains of Gram positive microorganisms (including MRSA)  Non-inf compared with vanc/linezolid  Lipoglycopeptide  Effective half life of 8.5d (204 hrs)  1000mg IV over 30min x1 followed by 500mg IV over 30min x1 (7d later)  Renal impairment (<30mL/min not on scheduled HD)  750mg IV over 30 min x1 followed by 375mg IV over 30 min x1 (7d later) No recommendations for HD patients.  May dialyze with high permeability membranes 24

25 Dalbavancin (Dalvance)  Unique aspects  LONG half-life  Two doses for ABSSSI, but will two doses get done?  How do you deal with drug reactions and drug interaction issues?  Redman can happen with rapid infusion  Category C  Currently one indication, potential for abuse?  Quite expensive  At least $1500/500mg vial  May reduce cost by reducing hospitalization 25

26 Oritavancin (Orbactiv)  Indication for acute bacterial skin and skin structure infections caused susceptible strains of Gram positive microorganisms (including MRSA)  Non-inf compared with vancomycin  Lipoglycopeptide  Terminal half life of 245h, clearance 0.445L/h  1200mg IV over 3h x1 (reconstitute from 400mg vials)  Renal impairment >30mL/min, no dose adjustment required. <30mL/min no recommendation 26

27 Oritavancin (Orbactiv)  Unique aspects  LONG half-life, SINGLE dose for ABSSSI  How do you deal with drug reactions and drug interaction issues?  Redman can happen with rapid infusion  More cases of osteomyelitis reported in oritavancin arm as compared with vancomycin arm.  Artificially prolonged aPTT for 48h and PT/INR for up to 24h.  Category C  Currently one indication, potential for abuse?  Expected to be expensive  May reduce cost by reducing hospitalization 27


Download ppt "New Antimicrobials Agents Michael J. Tan, MD, FACP, FIDSA Associate Professor of Internal Medicine, Northeast Ohio Medical University Summa Health System,"

Similar presentations


Ads by Google